Alaunos Therapeutics, Inc. is a biotechnology company. The Company's obesity and metabolic disorders program is advancing ALN1003, an oral small-molecule candidate being evaluated as a potential differentiated, non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology. ALN1003 is a preclinical, non-incretin, oral candidate targeting metabolic dysfunction beyond weight loss that may address insulin resistance, adipose signaling, liver biology, and body composition. ALN1003 is a preclinical, oral, non-hormonal metabolic therapeutic candidate being evaluated for: obesity-related metabolic dysfunction, MASH-relevant biology, and insulin resistance. The Company is advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. The Company is developing ActRII-Fc ligand traps and complementary biologics. The Company's programs include VLR199, VLR247, VLR258, VLR360 and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
26-10-23	US$2.280	-25.00%
26-10-22	US$3.040	-1.30%
26-10-21	US$3.080	+3.70%
26-10-20	US$2.970	-5.11%
26-10-19	US$3.130	+19.01%

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alaunos Therapeutics, Inc.

Company calendar

Market Closed - Nasdaq 16:00:00 2026-10-23 EDT			5-day change	1st Jan Change
2.280 ^USD	-25.00%		-13.31%	-29.41%

10-16	Top Premarket Gainers	MT
10-13	Alaunos Therapeutics Enters into Agreement and Plan of Merger with Velaris Therapeutics	CI

Market Cap	5.79M 5.17M 4.78M 4.33M 8.1M 550M 8.24M 57.5M 22.77M 288M 21.74M 21.28M 908M	P/E 2024	-0.65x	P/E 2025	-1.47x
Enterprise Value	4.41M 3.94M 3.64M 3.29M 6.16M 418M 6.27M 43.75M 17.32M 219M 16.54M 16.19M 691M	EV / Sales 2024	195,938,500x	EV / Sales 2025	1,164,761,400x
Free-Float	87.59%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq	TCRT	Delayed
CBOE	TCRT	Real-time

10-16	Top Premarket Gainers	MT
10-13	Alaunos Therapeutics Enters into Agreement and Plan of Merger with Velaris Therapeutics	CI
10-13	Alaunos Therapeutics, Inc. Appoints Peter Harwin to Board of Directors	CI
10-13	Top Midday Gainers	MT
10-13	Alaunos Therapeutics, Inc. announced that it expects to receive $349.953008 million in funding	CI
10-13	Alaunos Therapeutics Completes Velaris Acquisition; Shares Surge	MT
10-12	Alaunos Therapeutics, Inc. acquired Velaris Therapeutics, Inc.	CI
10-06	Certain Warrants of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	Certain Stock Options of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-06	Certain Common Stock of Alaunos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
08-14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study	CI
05-26	Alaunos Therapeutics Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	CI

Alaunos Therapeutics, Inc. Stock

Stocks

TCRT

US98973P3091

Biotechnology & Medical Research

Valuation: Alaunos Therapeutics, Inc.

Chart: Alaunos Therapeutics, Inc.

Latest news: Alaunos Therapeutics, Inc.

Analysts' recommendations: Alaunos Therapeutics, Inc.

Press Releases: Alaunos Therapeutics, Inc.

News in other languages: Alaunos Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Alaunos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

23-08-16	HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy	MT
23-08-15	Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy	MT
22-10-04	Wells Fargo Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
22-07-15	Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
22-05-04	Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight	MT

09-18	Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules	AQ
08-14	Ziopharm: Q2 Earnings Snapshot	AQ
06-29	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study	AQ
05-26	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	AQ
05-18	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models	AQ

15-06-30	Alibaba : Les valeurs à suivre sur les marchés américains
15-06-30	USA-Les valeurs à suivre à Wall Street

Manager	Title	Age	Since
Holger Weis CEO	Chief Executive Officer	63	2025-07-01
Ferdinand Groenewald DFI	Director of Finance/CFO	42	2025-02-21

Director	Title	Age	Since
Holger Weis CHM	Chairman	63	2023-09-21
Peter Harwin BRD	Director/Board Member	40	2026-10-12

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/6/26	Holger Weis	Free	Chief Executive Officer	23,564	0.9275%
10/6/26	Jaime Vieser	Free	Director	22,669	0.8923%
10/6/26	Robert Postma	Free	Director	21,829	0.8592%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALAUNOS THERAPEUTICS, INC.	-25.00%	-13.31%	-	-	5.79M
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+42.02%	+71.57%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+27.03%	+52.07%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.80%	+123.81%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+249.91%	+918.74%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.26%	+58.53%	33.52B
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.65%	23.97B
Average	-2.25%	+0.84%	+49.51%	+157.55%	38.31B
Weighted average by Cap.	+0.39%	+2.73%	+47.57%	+158.58%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.1 0.04 0.5 0.04 0.04 1.57	0 0 0 0 0.01 0.47 0.01 0.05 0.02 0.25 0.02 0.02 0.78
Net income	-4.68M -4.18M -3.86M -3.5M -6.54M -444M -6.65M -46.45M -18.39M -233M -17.56M -17.19M -734M	-4.18M -3.73M -3.45M -3.12M -5.84M -396M -5.94M -41.46M -16.41M -208M -15.67M -15.34M -655M
Net Debt	-1.09M -974K -900K -816K -1.53M -104M -1.55M -10.83M -4.29M -54.26M -4.09M -4.01M -171M	-1.38M -1.24M -1.14M -1.04M -1.94M -131M -1.97M -13.75M -5.44M -68.89M -5.2M -5.09M -217M